tbuckley/cabot-search huggingface dataset:
Phase II trial of iodine 131-labeled murine anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection cavity in the treatment of patients with recurrent malignant brain tumors
Authors: M. A. Badruddoja, D. A. Reardon, G. Akabani, A. H. Friedman, H. S. Friedman, J. N. Rich, J. A. Quinn, K. Penne, J. J. Vredenburgh, D. D. Bigner
Journal: Journal of Clinical Oncology (2004)

1569 Background: In a prior phase I study we established the dose of 100mCi as the maximum tolerated dose of iodine 131-labeled murine anti-tenascin antibody 81C6 (131I-81C6) injected into a surgically created resection cavity (SCRC) for the treatment of recurrent malignant glioma in adult patients. Methods: In the current phase II study we have treated 42 patients with recurrent brain tumors (GBM=32, AA=6, AO=2, infiltrating glioma = 1, metastatic =1). Patients were included into study if they had: 1) gross total resection, 2) KPS > 60%, 3) normal bone marrow and normal hepatic and renal function. All patients had received standard external beam radiation and 14 (33%) patients had received prior chemotherapy. Results: The median age was 54.5 years and 27 patients (64%) were males. All patients received 100mCi except for two patients that received 67mCi and 75mCi respectively due to the limited size of the SCRC. Toxicities were divided into acute (< 4 weeks), subacute (4–16 weeks) and delayed (>16 weeks) periods. Acute and sub-acute reversible, grade 4 hematologic toxicity was seen in 2 patients (4%) and 3 (7%) patients, respectively. Delayed grade 3 or 4 neurotoxicity was seen in 2 patients (4%). The median survival of all patients and GBM patients was 59 weeks for both groups, respectively. For patients with GBM the probability of 1-year survival is 0.56 (CI-95%; 0.41–0.78). As of December 16, 2003, 15 patients remain alive with a median follow up of 81.9 weeks for GBMs and 78.9 weeks for all patients. Conclusions: I131- labeled murine anti-tenascin antibody 81C6 is associated with minimal hematologic toxicity and provides an improvement in survival in patients with recurrent malignant glioma that have failed conventional therapy. No significant financial relationships to disclose.
A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
Authors: Harry P. Erba, Moshe Y Levy, Sumithira Vasu, Anthony S. Stein, Amir T. Fathi, Michael B. Maris, Anjali Advani, Stefan Faderl, Scott E. Smith, Brent L. Wood, Roland B. Walter, Jay Yang, William B. Donnellan, Eric J. Feldman, Jenna L Voellinger, Farhad Ravandi
Journal: Blood (2016)
EFFICACY AND SAFETY OF EVEROLIMUS-ELUTING STENTS VERSUS SLOW-RELEASE ZOTAROLIMUS-ELUTING STENTS: A DIRECT COMPARISON META-ANALYSIS OF 29,286 PATIENTS – YEARS OF FOLLOW-UP FROM RANDOMIZED CONTROLLED TRIALS
Authors: Chirag Bavishi, Habib Samady, Pedro Moreno, Gregg Stone
Journal: Journal of the American College of Cardiology (2017)
Screen time of over three hours a day is linked to diabetes risk factors in children
Authors: Zosia Kmietowicz
Journal: BMJ (2017)

Daily screen time of more than three hours is linked to several risk factors associated with the development of diabetes in children, including adiposity and insulin resistance, an observational study has found.

Previous research had indicated that spending a lot of time in front of a screen is linked to a heightened risk of weight gain and type 2 diabetes in adults, but whether children were also at risk was unclear. Researchers from London and Glasgow assessed nearly 4500 9-10 year olds from 200 primary schools in London, Birmingham, and …
The challenge of targeting cancer stem cells to halt metastasis
Authors: Alice Agliano, Alfonso Calvo, Carol Box
Journal: Seminars in Cancer Biology (2017)

Despite a continuing debate about the existence of cancer stem cells (CSCs), recent discoveries have provided further support for their existence and their roles in drug resistance, cancer recurrence and metastasis. CSC characteristics, such as self-renewal and tumour initiation, and supporting cellular processes, particularly the epithelial-to-mesenchymal transition, are attracting a great deal of attention from cancer researchers as they offer opportunities for discovering novel therapeutic targets for future drug development. However, the identification of potential CSC targets presents clear obstacles due to a lack of truly specific CSC markers and the reality of CSC plasticity, making this task a significant challenge. Agents that target developmental signalling pathways, such as Notch, Wnt and Hedgehog, are now in clinical trials whilst alternative approaches including immune-based therapies and microRNA-mediated pathway inhibitors are producing promising pre-clinical results. Here, we discuss the contribution of CSCs to cancer metastasis and the scope of opportunities for therapeutic intervention. In particular, we consider CSC-targeting agents for which there is experimental evidence of anti-metastatic properties and which may have potential to eventually limit relapse and impede metastasis in patients.
Health and quality of life (QOL) issues in four groups of lung cancer patients: Low-dose computed tomography (LDCT) screened, chest x-ray detected, incidentally found, and routinely diagnosed.
Authors: Ping Yang, Kathleen J. Yost, Matthew M. Clark, Mariza de Andrade, Katherine M. Piderman, Jason A. Wampfler, Jeff A. Sloan, David E. Midthun
Journal: Journal of Clinical Oncology (2012)

1610 Background: Low dose computed tomography (LDCT) scans have reduced lung cancer deaths by 20.3% in high risk populations, although there is an unknown balance between the benefits and harms of LDCT scans as a screening tool. Our purpose was to compare health-related QOL issues among lung cancer patients who were initially detected by LDCT scans; 4 comparison groups included: lung cancer diagnosed by a screening chest X-ray, as an incidental finding from procedures taken for other medical reasons, or based on symptoms indicative for lung cancer and routinely diagnosed, and individuals who were LDCT screened but found no lung cancer (controls who participated in Mayo’s lung cancer CT screening trial). Methods: A total of 1,658 lung cancer patients (cared at Mayo Clinic) in the 4 groups (37, 151, 389, and 1081 respectively) and 488 controls were compared on following patient-reported outcomes (collected via validated tools): overall QOL, four symptoms (cough, pain, dyspnea, fatigue), mental/ physical/ emotional/ social/ spiritual QOL, and other concerns (e.g., family/ friends/ financial/ legal). A clinically significant deficit was defined as at least 10-points in difference (or &lt;50 points) on a 0-100 scale. The rates of deficits were compared via Fisher’s exact tests and average QOL values via Kruskal-Wallis tests. Results: Overall QOL and individual symptoms were significantly worse (p&lt;0.05) in all lung cancer groups than in controls, except for pain. LDCT-screened patients reported the greatest deficit among the 4 lung cancer groups in physical (41%), emotional (24%), social (38%), and spiritual QOL (24%); whereas chest X-ray detected patients had the least deficit in overall QOL (22%) and pain (32%). All 4 lung cancer groups experienced much worse fatigue (52-64%) than the controls (32%). Conclusions: Our preliminary results suggest that LDCT-screening detected lung cancer patients reported a different QOL profile from other lung cancer patients and non-lung cancer controls. The clinical course, smoking behavior, and QOL related health issues associated with LDCT screening for lung cancer warrant thorough investigation.
CHANGES IN PREVALENCE, PROGRESSION AND OUTCOMES OF CORONARY ALLOGRAFT VASCULOPATHY OVER 25 YEARS FOLLOWING CARDIAC TRANSPLANTATION: A SINGLE CENTER EXPERIENCE
Authors: Maxime Tremblay-Gravel, Normand Racine, Anique Ducharme, Guy Pelletier, Genevieve Giraldeau, Mark Liszkowski, Marie-Claude Parent, Michel Carrier, Annik Fortier, Michel White
Journal: Journal of the American College of Cardiology (2017)
Increased Mitochondrial Mass and Mitochondrial DNA Copy Number Are Biomarkers for Benzene Exposure in Hematopoietic Tissue and Leukemia Cells.
Authors: Myung-Geun Shin, Ha-Young Eom, Hye-Ran Kim, Aerin Kwon, Dong kyun Han, Hee-Jo Baek, Jong-Hee Shin, Soon-Pal Suh, Dong-Wook Ryang, Tai Ju Hwang, Hoon Kook
Journal: Blood (2009)
WIDE COMPLEX TACHYCARDIA IN A 51-YEAR-OLD MAN: VENTRICULAR TACHYCARDIA UNTIL PROVEN OTHERWISE?
Authors: Junaid Ahmed Zaman, Sandeep Nair, Ali Sovari, Charles Swerdlow, Sumeet Chugh, Eugenio Cingolani, Michael Shehata, Xunzhang Wang, Ashkan Ehdaie, Eli Gang
Journal: Journal of the American College of Cardiology (2017)
CLINICAL EFFICACY OF HIGH-FLOW OXYGEN THERAPY THROUGH NASAL CANNULA IN PATIENTS WITH ACUTE HEART FAILURE
Authors: Min Gyu Kang, Hyun Woong Park, Jin-Sin Koh, Seok-Jae Hwang, Jin-Yong Hwang, Jong-Hwa Ahn, Yongwhi Park, Young-Hoon Jeong, Choong Hwan Kwak, Jeong-Rang Park
Journal: Journal of the American College of Cardiology (2017)
BENEFICIAL EFFECT OF STATIN THERAPY ON CAROTID WALL TEMPERATURES IN PATIENTS WITH FAMILIAL HYPERLIPIDEMIA SYNDROMES: RESULTS FROM A RANDOMIZED TRIAL
Authors: Georgios Benetos, Konstantinos Toutouzas, Iosif Koutagiar, Ioannis Skoumas, Spyros Galanakos, Angeliki Rigatou, Constantina Aggeli, Eleftherios Tsiamis, Elias Siores, Dimitris Tousoulis
Journal: Journal of the American College of Cardiology (2017)
Acquired Hemophagocytic Syndrome in Patients with Lymphoma: Clinical and Molecular Features in 15 Patients of Western Origin
Authors: Marina Motta, Chiara Bottelli, Chiara Cattaneo, Giovanna Tabellini, Silvia Parolini, Marco Ungari, Fabio Facchetti, Gianfranco Savoldi, Patrizia Mella, Giuseppe Rossi
Journal: Blood (2008)
Successful Engraftment Using Varied Stem Cell Sources, Low Toxicity, and Long-Term Survival Using a Bu/Flu/ATG Reduced Intensity Allogeneic Transplantation in High Risk Pediatric Patients Ineligible for Myelablative Therapy: Results of the Pediatric Blood and Marrow Transplant Consortium (PBMTC) Study ONC0313.
Authors: Michael A. Pulsipher, Haydar Frangoul, Michel Duval, Rakesh Goyal, Peter J. Shaw, Ann Haight, Richard Kadota, Michael Grimley, Stephan A. Grupp, Morris Kletzel
Journal: Blood (2007)
Tumor markers as predictors of outcome in patients with advanced esophagogastric adenocarcinoma (EGA) treated with chemotherapy.
Authors: Maria Gion Cortés, Silvia Patricia Cortez Castedo, Federico Longo, Reyes Ferreiro Monteagudo, Vanessa Pachón Olmos, Mercedes Rodríguez Garrote, Maria Alsina, Jacobo Muñoz del Toro, Alfonso Cortés Salgado, Pablo Reguera Puertas, Ainhoa Madariaga Urrutia, Maria Villamayor Delgado, Olga Martinez Saez, Javier Molina CerrilloMD, Ana Gomez, Eduardo Roberts, Maria Eugenia Olmedo Garcia, Enrique Grande, Carmen Guillén Ponce, Alfredo Carrato
Journal: Journal of Clinical Oncology (2015)

e15061 Background: The clinical usefulness of tumor markers (TM) as predictors of treatment outcome in advanced EGA has been poorly defined. The aim of this study was to evaluate the prognostic significance of serum carcinoembryonic antigen (CEA), carbohydrate antigen (CA19-9) and cancer antigen 125 (CA125) levels in these patients. Methods: From April 2011 through October 2014, baseline and nadir serum levels of CEA, CA19-9 and CA125 were detected in 67 patients diagnosed with metastatic EGA treated with first line treatment, and TM reduction ratio was calculated. Chemotherapy efficacy was evaluated according to RECIST 1.1, and the relationship between TM response, chemotherapy efficacy, several clinicopathological features, and survival were determined by Cox regression analyses. Results: Data of 67 patients (median age 67 years, range 42-88) were analyzed retrospectively. The most usual histological subtype was diffuse (31.3%); G3 histologic in 20.9%; Her2 overexpression in 22.4%. Fifty-one patients (76.1%) were diagnosed with advanced disease. The proximal stomach was the primary site in 79.1%. Elevated serum CEA, CA19-9 and CA125 levels were determined in 42 (62.7%), 37 (55.2%) and 37 (55.2%) respectively, and all TM were elevated in 23 (34.3%). We found a reduction in the three TM levels in only 17 patients (25.4%). Seventeen patients (25.4%) achieved a radiological partial response and stable disease in 14%. In the univariable analysis, PFS was significantly longer in those patients with TM reduction in both CEA (12 vs 4 months; P = 0.000), CA19-9 (17 vs 6 months; P = 0.001), CA125 (12 vs 5 months; P = 0.029) compared with non-responders; whereas the baseline TM levels were not significantly correlated with survival. The effect of ratio TM reduction had an independent prognostic value: CEA [HR:2.447 (IC95%1.198-4.997),P = 0.014], CA19-9 [HR:2.752 (IC95%1.304-5.807),P = 0.008], CA125 [HR:2.134 (IC95%1.079-4.221),P = 0.029]. Conclusions: Serum CEA, CA19-9 and CA125 levels may add useful information in patients with advanced EGA predicting patient survival. Further data analyses would be helpful to develop a predictive model for tumor response.
USE OF TANDEMHEART AS A BRIDGE TO SURGERY IN A PATIENT WITH COMBINED OBSTRUCTIVE AND CARDIOGENIC SHOCK DUE TO MECHANICAL MITRAL VALVE THROMBOSIS
Authors: Ahmet Afsin Oktay, Stacy Mandras, James Jenkins, Todd Rosenthal, Alban De Schutter, Selim Krim
Journal: Journal of the American College of Cardiology (2017)
Bone Marrow Macrophage Galectin-3 Regulates Platelet Production through Recognition of O-Glycans on Megakaryocytes
Authors: Melissa M Lee-Sundlov, Renata Grozovsky, Silvia Giannini, Martina McGrath, Haley E Ramsey, Martha Sola-Visner, Karin M. Hoffmeister
Journal: Blood (2016)
PROLONGED INTER-FACILITY TRANSFER TIMES AND HOSPITAL LENGTH OF STAY IN INSURED PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION
Authors: Alexander Urban, Vinh Duong, Mark Heckle, Manyoo Agarwal, Tamunoinemi Bob-Manuel, Jeremy Brooksbank, Benjamin Zambetti, Showkat Haji, Uzoma Ibebuogu, Guy Reed, Rami Khouzam
Journal: Journal of the American College of Cardiology (2017)
RISK FACTORS ASSOCIATED WITH INFECTIVE ENDOCARDITIS AFTER AORTIC VALVE REPLACEMENT
Authors: Lauge Østergaard, Nana Valeur Køber, Lars Køber, Nikolaj Ihlemann, Henning Bundgaard, Gunnar Gislasson, Christian Torp-Pedersen, Niels Eske Bruun, Emil Loldrup Fosbøl
Journal: Journal of the American College of Cardiology (2017)
The attainment of life goals by adult survivors of childhood cancer
Authors: D. B. Crom, S. Lensing, S. Rai, M. Snider, M. M. Hudson
Journal: Journal of Clinical Oncology (2007)

9536 Background: Adult survivors of childhood cancer are at risk for disease- and therapy-related morbidity, which can adversely affect marriage and employment status, ability to obtain health insurance and access to care. Our aim was to identify factors associated with survivors’ ability to achieve these goals. Methods: We surveyed 1,437 survivors of different types of childhood cancer who were &gt;18 years of age and &gt;10 years from diagnosis. We compared our cohort's data to normative data in the Medical Expenditure Panel Survey and the Current Population Surveys of the U.S. Census Bureau. Survivors were categorized into 3 groups (hematological malignancy, solid tumors, or central nervous system tumors) and whether they had received radiation therapy. Results: The majority of respondents (response rate 65%) were survivors of hematological malignancies (71%), white (91%), and working full-time (62%); (43%) were married. When compared to age- and gender-adjusted national averages, only survivors of hematological malignancy who received radiation therapy were significantly less likely to be married than the general population (44% vs. 52%). Full-time employment among survivors was lower than national norms, except for survivors of hematological malignancy who had not received radiation therapy. The prevalence of having any health insurance, especially public insurance, was higher in all diagnostic groups than in the general population. Difficulty obtaining care was reported by 11% of all survivors; 12% reported not receiving needed health care. Additionally, 26.9% reported having been denied insurance. Current unemployment and lack of insurance were significantly associated with difficulty in obtaining care (p=0.049 and p&lt;0.001, respectively). CNS tumor survivors reported greater difficulty in obtaining needed care (p=0.030). Current employment and solid tumor diagnosis were associated with lower rates of denial of insurance (p=0.018 and p=0.003, respectively). Conclusion: Subgroups of adult childhood cancer survivors are at risk of problems with attaining life goals, including access to care. This has serious implications given the known long-term secondary medical complications in this at- risk population. No significant financial relationships to disclose.
Engineered Exosomes Expressing HLA and Co-Stimulatory Molecules to Generate Antigen-Specific CD8+ T Cells for Adoptive Cell Therapy
Authors: Sueon Kim, Hyun-Jung Sohn, Hyun-Joo Lee, Dae-Hee Sohn, Seung-Joo Hyun, Hyun-Il Cho, Il-Hoan Oh, Tai-Gyu Kim
Journal: Blood (2016)
MACROPHAGE MIGRATION INHIBITORY FACTOR SERUM LEVELS AND ITS ASSOCIATION WITH ACUTE CORONARY SYNDROME IN PATIENTS WITH DIABETES MELLITUS TYPE 2 FROM WESTERN MEXICO
Authors: Heriberte-Ontiveros Mercado, Jose Francisco Munoz-Valle, Lorena Valerdi Contreras, Jorge Ramon Padilla-Gutierrez, Jorge Eduardo Hernandez-del-Rio, Miriam Sagrario Alvarez-Villanueva, Emmanuel Valdes-Alvarado, Sarai Citlalic Rodriguez-Reyes, Yeminia Valle
Journal: Journal of the American College of Cardiology (2017)
EFFICACY AND SAFETY OF THE PCSK9 INHIBITOR ALIROCUMAB 300 MG EVERY 4 WEEKS IN INDIVIDUALS WITH TYPE 2 DIABETES ON MAXIMALLY TOLERATED STATIN THERAPY
Authors: Dirk Müller-Wieland, Daniel Rader, Patrick Moriarty, Jean Bergeron, Gisle Langslet, Kausik Ray, Garen Manvelian, Desmond Thompson, Maja Bujas-Bobanovic, Eli Roth
Journal: Journal of the American College of Cardiology (2017)
Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy as treatment of unresected locally advanced head and neck cancer squamous cell cancer (HNSCC): A meta-analysis of randomized trials.
Authors: Wilfried Budach, Edwin Boelke, Kai Kammers, Stephan Gripp, Christiane Matuschek
Journal: Journal of Clinical Oncology (2014)

6012 Background: Induction chemotherapy with docetaxel. cisplatin, and 5FU (TPF) before radiotherapy or chemoradiation (RT-CHX) has been shown to improve overall survival compared to induction chemotherapy with cisplatin and 5 FU in locally advanced HNSCC. Whether TPF induction before chemoradiation improves clinical outcome in comparison to chemoradiation is still a matter of debate. Recently, the results of 4 randomized trials addressing this question have become available. Methods: In the 4 trials of interest, in total 802 patients with locally advanced HNSCC were randomly assigned to receive either TPF induction chemotherapy followed by concurrent RT-CHX or concurrent RT-CHX. Platin or taxane based chemotherapy was used during radiotherapy (2x1.5 Gy and 1.8- 2 Gy in 30-35 fractions). 416 had oropharyngeal, 114 hyopharyngeal, 78 laryngeal, 143 oral cavity and 52 other HNSCC. Published hazard ratios and hazard ratios extracted from available survival curves for overall survival (OS) and progression free survival (PFS) were basis of the meta-analysis. Meta-analysis of the effect sizes on OS and PFS was performed using a random effects model based on parameter estimates of log hazard ratios in Cox models and their standard errors. Results: Additional induction chemotherapy with TPF before RT-CHX did not result in an improvement of overall survival (Hazard Ratio: 1.008, 95% confidence limits (CL) 0.816-1.246, p=0.940). A modest and statistically not significant benefit was observed in terms of PFS (Hazard Ratio: 0.881, 95% CL 0.723-1.073, p=0.207). Conclusions: Additional induction chemotherapy with TPF before RT-CHX does not improve overall survival in HNSCC.
ANGIOGRAPHIC PHENOTYPE AND CLINICAL OUTCOMES OF PATIENTS WITH MALIGNANCY UNDERGOING PCI
Authors: Michela Faggioni, Usman Baber, Madhav Sharma, George Danias, Annapoorna Kini, Jaya Chandrasekhar, Clayton Snyder, George Dangas, Srushti Shah, Nitin Barman, Sabato Sorrentino, Choudhury Hasan, Jason Kovacic, Gennaro Giustino, Joseph Sweeny, Pooja Vijay, Melissa Aquino, Serdar Farhan, Pedro Moreno, Srinivas Kesanakurthy, Vishal Kapur, Roxana Mehran, Samin Sharma
Journal: Journal of the American College of Cardiology (2017)
INFECTIVE ENDOCARDITIS AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT: INSIGHTS FROM THE NATIONWIDE READMISSIONS DATABASE
Authors: Dhaval Kolte, Andrew Goldsweig, J. Abbott, Paul Gordon, Frank Sellke, Afshin Ehsan, Neel Sodha, Barry Sharaf, Herbert Aronow
Journal: Journal of the American College of Cardiology (2017)
THE ROLE OF ORAL BETA BLOCKER IN A REAL-WORLD POPULATION WITH NON-ST SEGMENT ELEVATION ACUTE CORONARY SYNDROMES
Authors: Jose C. Nicolau, Aline Ferrari, Gabriela M.M. Coelho, Carlos A.K. Nakashima, Viviane M. Lima, Talia Dalcoquio, Remo Furtado, Fernando Menezes, Jose Ramires, Roberto Kalil-Filho, Luciano Baracioli
Journal: Journal of the American College of Cardiology (2017)
Comprehensive genomic profiling of metastatic gastric cancer undergoing palliative chemotherapy at Samsung Medical Center using custom targeted deep sequencing (CancerSCAN<sup>™</sup>).
Authors: Jeeyun Lee, Seung Tae Kim, Tae Sohn, Sung Kim, Se Hoon Park, Woong Park, Kyoung Mee Kim, Jae Bae, Won Ki Kang
Journal: Journal of Clinical Oncology (2015)

e22173 Background: Although the comprehensive genome-wide profiling in gastric cancer (GC) has been reported by the TCGA and the ACRG, few studies focused on exploring therapeutic targets in metastatic GC patients in a large scale. This study was to lay groundwork for personalized therapy using CancerSCAN Methods: We use CancerSCAN, an Illumina HiSeq2500-based platform comprising SNV, CNV, INDEL and chromosomal rearrangements covering 381 genes. Results: From 2010 Jan to July 2014, 1,795 GC patients received palliative chemotherapy at SMC. Of 1,795 patients, 704 patients had adequate tumor tissue specimens for DNA extractions. Of 704 patients, the distribution of histologic subtypes is as follows: 491 adenocarcinoma NOS or tubular adenocarcinoma, 158 signet ring cell carcinoma, 18 mucinous adenocarcinoma, 18 papillary adenocarcinoma, 19 others. By anatomic locations, 658 were body to antrum GC and 34 were cardia GC. Of 704 patients, 524 patients had sufficient amount of DNA from paraffin-embedded tissue specimens (at baseline) for further genome analysis. Conclusions: 524 patients entered the deep target sequencing and 524 patients will be molecularly dissected by genome sequencing. The data will be presented at the annual meeting of ASCO.